Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

The cost-effectiveness of male HPV vaccination in the United States.

Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.

Vaccine. 2011 Oct 26;29(46):8443-50. doi: 10.1016/j.vaccine.2011.07.096.

PMID:
21816193
3.

[Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].

Westra TA, Daemen T, Postma MJ, Wilschut JC.

Ned Tijdschr Geneeskd. 2009;153:A356. Review. Dutch.

PMID:
19930733
4.
5.

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.

Koleva D, De Compadri P, Padula A, Garattini L.

Intern Emerg Med. 2011 Apr;6(2):163-74. doi: 10.1007/s11739-011-0529-3. Review.

PMID:
21312004
6.

Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.

Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.

Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280. Review.

PMID:
21361739
7.

Prevention strategies against human papillomavirus in males.

Garland SM.

Gynecol Oncol. 2010 May;117(2 Suppl):S20-5. doi: 10.1016/j.ygyno.2010.01.027. Review.

PMID:
20138347
8.

Human papillomavirus vaccine: a paradigm shift for pediatricians.

Jenson HB.

Curr Opin Pediatr. 2009 Feb;21(1):112-21. doi: 10.1097/MOP.0b013e3283207f93. Review.

PMID:
19242247
10.

Human papillomavirus vaccine and men: what are the obstacles and challenges?

Stupiansky NW, Alexander AB, Zimet GD.

Curr Opin Infect Dis. 2012 Feb;25(1):86-91. doi: 10.1097/QCO.0b013e32834ed5be. Review.

PMID:
22143118
11.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Review.

PMID:
17682997
12.

Anti-HPV vaccination: a review of recent economic data for Italy.

Mennini FS, Costa S, Favato G, Picardo M.

Vaccine. 2009 May 29;27 Suppl 1:A54-61. doi: 10.1016/j.vaccine.2009.02.052. Review.

PMID:
19480963
13.

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.

Syrjänen KJ.

Scand J Infect Dis Suppl. 2009;107:3-32. doi: 10.1080/00365540902887730. Review.

PMID:
19408160
14.

A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.

Jiang Y, Gauthier A, Postma MJ, Ribassin-Majed L, Largeron N, Bresse X.

Hum Vaccin Immunother. 2013 Nov;9(11):2285-95. Review.

15.

The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.

Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ.

Expert Rev Vaccines. 2015 Apr;14(4):589-604. doi: 10.1586/14760584.2014.990386. Review.

PMID:
25482311
16.

An overview on the implementation of HPV vaccination in Europe.

Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, Panatto D, Gasparini R, Boccalini S.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:128-35. Review.

PMID:
21245659
17.

Cost–effectiveness of catch-up programs in human papillomavirus vaccination.

de Peuter MA, Littlewood KJ, Annemans L, Largeron N, Quilici S.

Expert Rev Vaccines. 2010 Oct;9(10):1187-201. doi: 10.1586/erv.10.108. Review.

PMID:
20923269
18.

Prevention strategies against the human papillomavirus: the effectiveness of vaccination.

Stanley M.

Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S19-23. Review.

PMID:
17938013
19.

[Developments in HPV vaccination].

de Melker H, Kenter G, van Rossum T, Conyn-van Spaendonck M.

Ned Tijdschr Geneeskd. 2012;156(47):A5410. Review. Dutch.

PMID:
23171565
20.

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.

Fesenfeld M, Hutubessy R, Jit M.

Vaccine. 2013 Aug 20;31(37):3786-804. doi: 10.1016/j.vaccine.2013.06.060. Review.

PMID:
23830973

Supplemental Content

Support Center